{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"4"}]}],"title":"Any Grade increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}]}],"title":"Increase to Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"Increase to Grade 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"32"},{"groupId":"OG007","value":"9"}],"units":"Participants"}],"description":"Electrocardiogram (ECG) measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (\\<450 milliseconds \\[msec\\]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (\\>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported.","groups":[{"description":"Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 2 mg QD"},{"description":"Participants were administered once daily oral dose of 4 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 4 mg QD"},{"description":"Participants were administered once daily oral dose of 8 mg GSK525762","id":"OG002","title":"Part 1: GSK525762 8 mg QD"},{"description":"Participants were administered once daily oral dose of 16 mg GSK525762","id":"OG003","title":"Part 1: GSK525762 16 mg QD"},{"description":"Participants were administered once daily oral dose of 30 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 30 mg QD"},{"description":"Participants were administered once daily oral dose of 60 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 60 mg QD"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants were administered once daily oral dose of 100 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 100 mg QD"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.38 months of drug exposure","title":"Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD","type":"SECONDARY","unitOfMeasure":"Participants"}